E Watertown, Massachusetts Clinical Trials

A listing of E Watertown, Massachusetts clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 128 clinical trials
featured
INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma

The purpose of this study is to evaluate the safety and antitumor activity of INCB001158 in combination with daratumumab SC, compared with daratumumab SC alone, in participants with relapsed or refractory multiple myeloma who have received at least 3 but not more than 5 prior lines of multiple myeloma therapy. …

refractory multiple myeloma
daratumumab
Dana Farber Cancer Institute
 (4.5 away) Contact site
  • 71 views
  • 28 May, 2020
  • +27 other locations
featured
A Phase 1/2, Open-Label Clinical Study to Evaluate Safety and Efficacy of TP-0184 to Treat Anemia When Administered to Adult Patients with IPSS-R Low or Intermediate Risk of Myelodysplastic Syndromes

This is a Phase 1/2, open-label clinical study to evaluate preliminary safety and efficacy of TP-0184 to treat anemia when administered to adult patients with Revised International Prognostic Scoring System (IPSS-R) low or intermediate risk MDS.The recommended Phase 2 dose (RP2D) will be determined by the maximum tolerated dose (MTD) or …

Massachusetts General Hospital
 (5.9 away) Contact site
  • 0 views
  • 18 Jun, 2021
  • +2 other locations
featured
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation

Evaluates the safety, tolerability, pharmacokinetics, metabolites, pharmacodynamics, and clinical activity of MRTX849 in patients with advanced solid tumors with a KRAS G12C mutation. MRTX849 is an orally-available small molecule inhibitor of KRAS G12C.

malignant solid tumor
advanced solid tumor
solid tumor
Mirati Research Site
 (4.5 away) Contact site
  • 405 views
  • 08 Jul, 2021
  • +72 other locations
featured
A Phase 1/2 Trial of MRTX849 in Combination with TNO155 in Patients with Advanced Solid Tumors with KRAS G12C Mutation

Characterize the safety and tolerability, and evaluate Pharmacokinetics of MRTX849 in combination with TNO155 in patients with advanced solid tumor malignancies with KRAS G12C mutation. MRTX849 is an orally available small molecute inhibitor of KRASG12C. TNO155 is a selective, orally bioavailable allosteric inhibitor of wild type SHP2.

malignant solid tumor
advanced solid tumor
solid tumors
solid tumor
Dana Farber
 (4.4 away) Contact site
  • 114 views
  • 19 Feb, 2021
  • +9 other locations
A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors

To better understand the safety and tolerability of ALKS 4230 in humans

Alkermes Investigational Site
 (4.5 away) Contact site
  • 0 views
  • 02 May, 2021
  • +25 other locations
A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer

This study is about a medicine called TAK-788, also known as mobocertinib, given to adults with non-small cell lung cancer. The main aims of this study are to check if there are any side effects from TAK-788, to learn how TAK-788 is processed by the body, and to determine the …

lung carcinoma
HER2
carboplatin
systemic therapy
pemetrexed
Beth Israel Deaconess Medical Center
 (4.4 away) Contact site
  • 0 views
  • 31 May, 2021
  • +97 other locations
Safety and Efficacy of Efavaleukin Alfa in Subjects With Steroid Refractory Chronic Graft Versus Host Disease

Phase 1b: To evaluate the safety and tolerability of multiple ascending doses of efavaleukin alfa in subjects with steroid refractory chronic graft versus host disease (cGVHD). Phase 2: To evaluate the efficacy of efavaleukin alfa in subjects with steroid refractory cGVHD as measured by overall response rate (ORR) at 16 …

Dana Farber Cancer Institute
 (4.5 away) Contact site
  • 12 views
  • 12 Jun, 2021
  • +28 other locations
A Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors

The purpose of this first-in-human (FIH) study of BLZ945 given as a single agent or in combination with PDR001 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and anti-tumor activity of BLZ945, administered orally, as a single agent or in combination with PDR001, administered intravenously (i.v.) in adult patients …

Dana Farber Cancer Institute Dana Farber Cancer Institute
 (4.5 away) Contact site
  • 0 views
  • 02 Aug, 2021
  • +17 other locations
CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma

This study is being conducted to test the safety and efficacy of ramucirumab in combination with other chemotherapy in the treatment of relapsed, recurrent, or refractory synovial sarcoma (SS) in children and young adults. This trial is part of the CAMPFIRE master protocol which is a platform to accelerate the …

Dana-Farber Cancer Institute
 (4.5 away) Contact site
  • 0 views
  • 24 Jul, 2021
  • +68 other locations
Senicapoc and Dehydrated Stomatocytosis

Dehydrated stomatocytosis is a genetic disorder characterized by chronic hemolysis, variable anemia and erythrocyte dehydration. Causative mutations have been identified in either the Gardos (KCNN4) channel or the mechanosensitive channel PIEZO1. Senicapoc is a selective blocker of the Gardos channel that has been extensively studied in sickle cell disease and …

Boston Children's Hospital
 (5.2 away) Contact site
  • 0 views
  • 13 Jun, 2021
  • 1 location